In the claims:

Claim 1 (currently amended): A method of producing a mammalian cell for packaging of a recombinant AAV (rAAV) vector, said method comprising ~~the steps of~~:

[[(a)]] replicating a mammalian cell to produce a population of cells; wherein the mammalian cell comprises a stably integrated AAV cap gene operably linked to AAV p40 promoter, and a stably integrated AAV rep gene operably linked to a helper virus-inducible heterologous promoter, wherein (a) the AAV cap gene and the AAV rep gene are stably integrated into the mammalian cell's genome [[,]]; (b) ~~wherein~~ p5 promoter function has been replaced by the helper virus-inducible heterologous promoter; (c) ~~and wherein~~ said mammalian cell [[is]] was prepared by introducing a ~~single~~ plasmid comprising both AAV rep and AAV cap arranged as in the AAV genome into the mammalian cell; and (d) upon introduction of a helper virus into the population of the cells, said cells exhibit

~~(b) introducing a helper virus to the population of cells of step (a); and~~

~~(c) wherein said cell exhibits~~ helper virus-inducible expression of said stably integrated AAV rep gene.

Claim 2 (previously presented): The method according to claim 1, wherein said helper virus is an adenovirus.

Claim 3 (currently amended): The method according to claim 1, wherein said ~~packaging~~ mammalian cell grows at least one half as rapidly as parental-type cells that do not contain an AAV rep gene, and wherein said ~~packaging~~ mammalian cell when used to package rAAV vectors produces at least 100 rAAV particles/cell.

Claim 4 (cancelled)

Claim 5 (previously presented): The method according to any of claims 1-3, wherein said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.

Claim 6 (currently amended): A cell produced by the method of claim 1, and progeny thereof[[,]] ~~wherein said cell exhibits helper-virus-inducible expression of said stably integrated AAV rep gene~~.

Claim 7 (currently amended): A cell produced by the method of claim 3, and progeny thereof[[,]] ~~wherein said cell exhibits helper-virus-inducible expression of said stably integrated AAV rep gene~~.

Claim 8 (cancelled)

Claim 9 (currently amended): A cell produced by the method of claim 5, and progeny thereof[[,]] ~~wherein said cell exhibits helper-virus-inducible expression of said stably integrated AAV rep gene~~.

Claim 10 (currently amended): A mammalian cell for packaging of a recombinant AAV (rAAV) vector, said cell comprising a stably integrated cap gene operably linked to AAV p40 promoter, and a stably integrated rep gene operably linked to a helper virus-inducible heterologous promoter; wherein (a) the cap gene and the rep gene are stably integrated into the mammalian cell's genome; ~~wherein~~ (b) p5 promoter function has been replaced by the helper virus-inducible heterologous promoter; ~~wherein~~ (c) said cell exhibits helper-virus-inducible expression of said stably integrated AAV rep gene; and ~~wherein~~ (d) said mammalian cell [[is]] was prepared by introducing a ~~single~~ plasmid comprising both rep and cap arranged as in the AAV genome into the mammalian cell.

Claim 11 (previously presented): The AAV packaging cell of claim 10, wherein said helper-virus-inducible expression of said stably integrated AAV rep gene is inducible by adenovirus.

Claim 12 (previously presented): The AAV packaging cell of claim 10, wherein said packaging cell grows at least one half as rapidly as parental-type cells that do not contain an AAV

rep gene, and wherein said packaging cell when used to package rAAV vectors produces at least 100 rAAV particles/cell.

Claim 13 (cancelled)

Claim 14 (previously presented): The AAV packaging cell of any of claims 10-12, wherein said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.

Claim 15 (previously presented): The AAV packaging cell of claim 10, further comprising a stably integrated recombinant AAV (rAAV) vector, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter.

Claim 16 (currently amended): A method of packaging a recombinant AAV vector, comprising ~~the step of~~:

incubating [[an]] the AAV packaging cell of claim 10 under conditions suitable for replication and packaging of AAV ~~such that a recombinant AAV(rAAV) vector is packaged~~; wherein the AAV packaging cell further comprises: (a) an [[the]] rAAV vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter; and (b) ~~wherein the AAV packaging cell comprises~~ a helper virus; wherein the incubation results in packaged rAAV vector.

Claim 17 (currently amended) A method of packaging a recombinant AAV vector, comprising ~~the step of~~:

incubating ~~an~~ the AAV packaging cell of claim 15 under conditions suitable for replication and packaging of AAV ~~such that a stably integrated rAAV vector is packaged~~; wherein the AAV packaging cell further comprises a helper virus; ~~and wherein the AAV packaging cell comprises the stably integrated rAAV vector comprising a polynucleotide of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter~~ wherein the incubation results in packaged rAAV vector.

Claims 18-20 (cancelled)

Claim 21 (currently amended): A method of determining the infectious titer of an rAAV vector preparation, comprising ~~the steps of~~:

(a) introducing a helper virus and serial dilutions of [[the]] an rAAV vector preparation to the AAV packaging cells of claim 10;

(b) incubating the cells under conditions suitable for replication of AAV; and

(c) determining the amount of replicated rAAV vector relative to an rAAV preparation of known titer.

Claim 22-24 (cancelled)

Claim 25 (currently amended): A method of producing a mammalian cell for packaging of a recombinant AAV (rAAV) vector, said method comprising ~~the step of~~:

[[(a)]] introducing a ~~single~~ plasmid comprising both AAV rep and AAV cap arranged as in the AAV genome into a mammalian cell, wherein the AAV cap gene is operably linked to AAV p40 promoter and the AAV rep gene is operably linked to a helper virus-inducible heterologous promoter, wherein p5 promoter function has been replaced by the helper virus-inducible heterologous promoter; wherein the plasmid becomes stably integrated into the mammalian cell's genome; and wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene.

Claim 26 (currently amended): The method according to claim 25, wherein said ~~helper virus is an adenovirus~~ helper virus-inducible expression of said stably integrated AAV rep gene is inducible by adenovirus.

Claim 27 (currently amended): The method according to claim 25, wherein said ~~packaging~~ mammalian cell grows at least one half as rapidly as parental-type cells that do not

contain an AAV rep gene, and wherein said ~~packaging~~ mammalian cell when used to package rAAV vectors produces at least 100 rAAV particles/cell.

Claim 28 (previously presented): The method according to any of claims 25-27, wherein said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.

Claim 29 (currently amended): A cell produced by the method of claim 27, and progeny thereof[[,]] ~~wherein said cell exhibits helper virus-inducible expression of said stably integrated AAV rep gene~~.

Claims 30-32 (cancelled)

Claim 33 (currently amended): A method of packaging a recombinant AAV vector~~,~~ comprising ~~the step of~~:

incubating [[an]] the AAV packaging cell of claim 29 under conditions suitable for replication and packaging of AAV ~~such that a recombinant AAV (rAAV) vector is packaged~~; wherein the AAV packaging cell further comprises: (a) an [[the]] rAAV vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter; and ~~wherein the AAV packaging cell comprises~~ (b) a helper virus; wherein the incubation results in packaged rAAV vector.

Claims 34-38 (cancelled)

Claim 39 (previously presented): The method of claim 33, wherein said helper virus is an adenovirus.

Claims 40-41 (cancelled)